依达拉奉对帕金森病的疗效观察

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (34 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo study the clinical effect of Edaravone treating Parkinson disease (PD)of early and late stage.Methods36 patients with treated by our hospital from April 2015 to April 2016 were selected,and they were divided into PD of early stage group(≤3.5 years)and PD of late stage group(≥4 years).Patientswere treated by Edaravone of 30 mg added into 250 ml of 0.9%sodium chloride solution to intravenously drip for 2 times every day on the basis of the routine PD treatment,and drugswere used for 2 weeks.The unified rating scale of PD(UPDRS)was used to evaluate the curative effect after treatment,incidence of complications was observed,and serum Aβ1-42and BDNF between two groups before and after treatment were detected and compared.ResultsAfter treatment,mental activity,behavior and mind,daily living activity and motor examination of the UPDRS score in PD of early stage group were significantly decreased compared with before treatment(P＜0.05),while there was no significant differences of above-mentioned indexes in PD of late stage group before and after treatment(P＞0.05).The serum Aβ1-42and BDNF of PD of early stage group after treatmentwere higher than those of PD of late stage group(P＜0.05).In 36 cases,3 cases(8.33%)had abnormal liver function,rash and other adverse reactions,but all were mild,and recovered to normal after symptomatic treatment.ConclusionEdaravone has obvious effect to improve the condition of patients with PD in early stage,but the effect is not obvious in patientswith PD in late stage.

Key words： Edaravone Parkinson disease Curative effiect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Su

Cite this article:

WANG Su. Curative effect observation of Edaravone in Parkinson disease[J]. 中国当代医药, 2016, 23(34): 130-132.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2016/V23/I34/130

[1]	黄月，赵青赞，任秀花，等.依达拉奉对脂多糖诱导的PD大鼠模型神经保护作用的实验研究[J].中风与神经疾病杂志，2011，28（1）：53-54.
[2]	叶华，郭蕾，范录平，等.联合依达拉奉治疗帕金森病的临床观察[J].中国医院药学杂志，2010，30（23）：1998-2002.
[4]	李岩，孙圣刚，孔庆胜，等.依达拉奉、神经节苷酯对帕金森病模型大鼠的神经保护作用[J].中华行为医学与脑科学杂志，2010，19（4）：317-318.
[6]	徐芳，任士卿，王彦永，等.依达拉奉对脂多糖诱导的大鼠多巴胺能神经元变性保护作用的研究[J].脑与神经疾病杂志，2009，17（1）：64-67.
[7]	王允明，王爱菊，陈海燕.依达拉奉对急性脑梗死的治疗效果[J].实用医学杂志，2006，22（23）：2760.
[9]	林善华.中医药治疗帕金森病研究进展[J].中国医学创新，2014，11（13）：154-156.
[3]	Elmali N，Esenkaya I，KaradagˇN，et al.Effects of resveratrol on skeletalmuscle in ischaemia-reperfusion injury[J].Ulus Travma Acil Cerrahi Derg，2007，13（4）：274-280.
[5]	Yoshida H，Yanai H，Namiki Y，et al.Neuroprotective effects of edaravone：a novel free radical scavenger in cerebrovascular injury[J].CNSDrug Rev，2006，12（1）：9-20.
[8]	Amemiya S，Kamiya T，Nito C，et al.Shimon A，Tstsuski K. Anti-apoptotic and neuroprotective effects of edaravone following transient focal ischemia in rats[J].Eur JPharmacol，2005，516（2）：125-130.
[10]	刘国胜，廖益，赖慧娟.普拉克索治疗帕金森病的临床效果分析[J].中国当代医药，2015，22（31）：136-137，140.
[11]	叶琳琳，杨子超，李福春，等.抗氧化剂依达拉奉联合葛根素用于帕金森病治疗的临床观察[J].现代生物医学进展，2014，14（32）：6311-6314.
[12]	邓铃英.依达拉奉治疗血管源性帕金森综合征的临床分析[J].中国卫生标准管理，2015，6（19）：84-85.
[13]	王秀茹.血管源性帕金森综合征应用依达拉奉治疗的效果观察[J].中国卫生产业，2014，11（32）：36-37.
[14]	刘玉梅，李晶鑫，张丽娟，等.血管源性帕金森综合征采用依达拉奉治疗的临床分析[J].中国现代药物应用，2015，9（13）：163-164.
[15]	吴爱明.依达拉奉治疗血管源性帕金森综合征疗效观察[J].现代医药卫生，2015，31（17）：2658-2660.